<DOC> 
<DOCNO>1080723_business_story_9588633.utf8</DOCNO> 
<TEXT> 
         
The Telegraph - Calcutta (Kolkata) | Business | Two-fold jump in Lupin net 
                                                                                                                                                                                                                                                                                                                                                                       Two-fold jump in Lupin net 
          OUR BUREAU                          GROWTH PILL                                  
	Mumbai, July 22: Pharma major Lupin today announced a consolidated net profit of Rs 112.04 crore for the first quarter ended June 30, a two-fold growth over the same period a year ago, on the back of a steady growth in generic and branded formulation businesses.        
	The company had posted a net profit of Rs 55.88 crore in the first quarter of 2007-08, Lupin said in a filing to the Bombay Stock Exchange.        
	The consolidated total income rose 49.15 per cent to Rs 882.47 crore in the latest quarter from Rs 591.65 crore in the year-ago period.        
	Lupin Pharmaceutical has garnered a steady growth in prescriptions for generics as well as branded formulations during the quarter, the drug firm said.        
	During the first quarter, Lupin reported a standalone net profit of Rs 108.52 crore, a 34.45 per cent growth over the same period in the previous fiscal. The companys net profit stood at Rs 78.38 crore in the first quarter of 2007-08.        
	The total income rose to Rs 731.23 crore in the latest quarter from Rs 616.89 crore in the year-ago period.        
	Our investment in the European market and some of the emerging markets have begun to bear fruit, which will stand us in good stead. We are confident of building this momentum further in the coming quarter, Lupin managing director Kamal Sharma said.        
	The companys domestic formulation business grew 25 per cent, while the advanced markets formulation business in the US and Europe grew 69 per cent to clock sales of Rs 253 crore against Rs 149.4 crore in the year-ago period. During the quarter, the company launched Ramipril capsules in the US, while its Japanese business contributed 10 per cent to the overall revenues.        
	Buyout plan        
	As part of its inorganic growth plans, Lupin is eyeing more acquisitions in Japan and the emerging markets of Southeast Asia, Lupin chairman Desh Bandhu Gupta said.        
	Asian Paints         
	Asian Paints today announced a consolidated net profit of Rs 106.21 crore for the first quarter ended June 30, 2008, a growth of 29.6 per cent over the corresponding period a year ago. The companys consolidated net profit stood at Rs 81.93 crore for the quarter ended June 30, 2007.        
	The companys consolidated total income rose to Rs 1,252.27 crore for the first quarter of this fiscal from Rs 969.44 crore in the year-ago period.         
	The firm has registered a standalone net profit of Rs 98 crore for the quarter, an increase of 32.02 per cent compared with Rs 74.23 crore in the year-ago period. The total income increased to Rs 1,011.19 crore in the latest quarter.                                                                                                                                      
</TEXT> 
</DOC>